262 results on '"Ferrer Marín, Francisca"'
Search Results
2. Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology
3. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
4. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
5. CAPN1 (Calpain1)-Dependent Cleavage of STIM1 (Stromal Interaction Molecule 1) Results in an Enhanced SOCE (Store-Operated Calcium Entry) in Human Neonatal Platelets
6. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
7. miR‐146a−/− mice model reveals that NF‐κB inhibition reverts inflammation‐driven myelofibrosis‐like phenotype.
8. DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study.
9. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
10. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response
11. Review of the risk of thrombosis or bleeding upon abrupt anagrelide discontinuation in patients with essential thrombocythemia
12. Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.
13. The prognostic impact of non‐driver gene mutations and variant allele frequency in primary myelofibrosis.
14. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy
15. Successful ovarian stimulation and pregnancy in an infertile woman with chronic myeloid leukemia
16. Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.
17. DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational study
18. PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT-FREE REMISSION (TFR) IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS TREATED WITH TKI
19. P987: IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL
20. P990: NF-ΚB AND JAK/STAT PATHWAYS INHIBITION REVERSES FIBROSIS IN A MURINE MODEL OF INFLAMMATION-DRIVEN MYELOFIBROSIS
21. P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA
22. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
23. Prognostic risk models for transplant decision-making in myelofibrosis
24. Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them?
25. Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction
26. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
27. Application of IPSET‐thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.
28. Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients
29. Tyrosine kinase inhibitor dose reduction during the management of accelerated phase chronic myeloid leukemia
30. Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response
31. Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors
32. Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study
33. Real-World Data Analysis of the Molecular Response Kinetics within the Two First Years of the RELMC-NOVA Study in Newly Diagnosed Spanish CML-CP Patients Treated with Tirosin Kinasa Inhibitors (TKIs) in First Line
34. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
35. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
36. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
37. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
38. Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes
39. Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera
40. Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation
41. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
42. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.
43. Neonatal platelet physiology and implications for transfusion
44. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis
45. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
46. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide
47. Leukaemic Transformation in Patients with Haematological Disease Receiving Tumour Necrosis Factor Inhibitors
48. Qualitative and Quantitative Comparison of Plasma Exosomes from Neonates and Adults
49. Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms
50. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.